Author: WTN News

Is the American pharma industry going the way of the U.S. auto industry? Given what transpired in 2007, columnist Michael Rosen wonders about that in this edition of Yer Biotech Blues. The way Big Pharma has and likely will continue to scamble to recover lost...

In what is being called a logical next step in the evolution of a Wisconsin medical services software provider, EMSystem of West Allis has acquired the electronic patient care technology of a California company that makes and sells personal health records and other medical software....

Deltanoid Pharmaceuticals, a privately held pharmaceutical development company spun out of the University of Wisconsin-Madison, has announced the completion of a $12 million round of financing that will be used to advance therapies for the treatment of renal disease. The money comes from a group...

The University of Wisconsin-Madison has finalized an exclusive license with Enable IPC Corp. to develop and sell ultracapacitor technology. The agreement formalizes a relationship that began with a license option agreement that gave Enable IPC the option to license the ultracapacitor technology, an alternative to...

Where have all the people gone that know what they are talking about, especially the apparently arcane subject of network infrastructure? The question is posed by columnist and cocktail party imbiber James Carlini, who challenges policy makers and others to take the network competency test...

GE Healthcare's decision to push new compact ultrasound products is paying dividends. Three enhanced medical imaging products are primarily responsible for the generation of $175 million in revenue for ultrasound thus far in 2007, a robust 65 percent increase over the same period of 2006. ...

The legacy of UW Chancellor John Wiley is not confined to the UW-Madison campus, but throughout the state of Wisconsin, according to columnist Tom Still. In this edition of Inside Wisconsin, Still notes that Wisconsin businesses and campuses throughout the state, particularly UW-Milwaukee, have had...

Is “Return of the Dotcom Bust” coming to a business theater near you? Columnist Brad Spirrison thinks the $15 billion valuation for Facebook could be a prelude to a second "dot-comedy," and he quotes several venture capitalists that view this level of valuation as an...